ATX-304, an AMPK network activator, demonstrated metabolic benefits in a Phase 1b trial: elevated adiponectin, reduced triglycerides and liver fat, and an 8% increase in resting metabolic rate without mitochondrial toxicity. Early evidence supports further investigation in prediabetes and metabolic dysfunction.
Key Points
- 8% increase in resting metabolic rate with minimal weight loss
- Significant reductions in triglycerides, liver fat, and visceral adiposity
- AMPK activation achieved without depleting cellular ATP or triggering mitochondrial stress
Longevity Analysis
The metabolic gains observed—elevated adiponectin, improved hepatic lipid handling, and increased mitochondrial respiration without toxicity—address core mechanisms underlying metabolic aging. Rather than relying on weight loss alone, this agent enhances energy production capacity and signaling at the cellular level. The 8% increase in resting metabolic rate, achieved early in dose escalation, suggests substantial room for additional benefit at higher exposures. For individuals with prediabetes, restoring metabolic efficiency and mitochondrial function directly impacts glucose homeostasis and reduces systemic inflammation, addressing root causes rather than symptoms.
Original published by Longevity.Technology.